Parkinson's disease. Modification by 5-hydroxytryptophan.
D006916:5-Hydroxytryptophan / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001921:Brain / Q000378:metabolism; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D002986:Clinical Trials as Topic; D004357:Drug Synergism; D005069:Evaluation Studies as Topic; D005116:Extrapyramidal Tracts / Q000187:drug effects; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008297:Male; D008750:Methyldopa / Q000627:therapeutic use*; D008875:Middle Aged; D010300:Parkinson Disease / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000378:metabolism; D010648:Phenylacetates / Q000134:cerebrospinal fluid; D010919:Placebos; D012701:Serotonin / Q000378:metabolism*
D006834:Hydrazines; D010648:Phenylacetates; D010919:Placebos; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D008750:Methyldopa; D006916:5-Hydroxytryptophan; D002262:Carboxy-Lyases